J Biomed Opt. 2013 Dec;18(12):120504. doi: 10.1117/1.JBO.18.12.120504. ABSTRACT The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for…Continue Reading Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging
Mol Imaging Biol. 2014 Jun;16(3):372-82. doi: 10.1007/s11307-013-0692-1. Epub 2013 Nov 12. ABSTRACT PURPOSE: Cancer-specific endothelial markers available for intravascular binding are promising targets for new molecular therapies. In this study, a molecular imaging approach of quantifying endothelial marker concentrations (EMCI) is developed and tested in highly light-absorbing melanomas. The approach involves injection of targeted imaging…Continue Reading Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging
Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9025-30. doi: 10.1073/pnas.1213490110. Epub 2013 May 13. ABSTRACT The up-regulation of cell surface receptors has become a central focus in personalized cancer treatment; however, because of the complex nature of contrast agent pharmacokinetics in tumor tissue, methods to quantify receptor binding in vivo remain elusive. Here,…Continue Reading Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo
Fluorescent affibody peptide penetration in glioma margin is superior to full antibody
PLoS One. 2013 Apr 12;8(4):e60390. doi: 10.1371/journal.pone.0060390. Print 2013. ABSTRACT OBJECT: Fluorescence imaging has the potential to significantly improve neurosurgical resection of oncologic lesions through improved differentiation between normal and cancerous tissue at the tumor margins. In order to successfully mark glioma tissue a fluorescent tracer must have the ability to penetrate through the blood…Continue Reading Fluorescent affibody peptide penetration in glioma margin is superior to full antibody
Dual-tracer background subtraction approach for fluorescent molecular tomography
J Biomed Opt. 2013 Jan;18(1):16003. doi: 10.1117/1.JBO.18.1.016003. ABSTRACT Diffuse fluorescence tomography requires high contrast-to-background ratios to accurately reconstruct inclusions of interest. This is a problem when imaging the uptake of fluorescently labeled molecularly targeted tracers in tissue, which can result in high levels of heterogeneously distributed background uptake. We present a dual-tracer background subtraction approach,…Continue Reading Dual-tracer background subtraction approach for fluorescent molecular tomography